- Friday, Jan. 24, 2020 (Moreton Building)
- 1100 W 49th St, Austin, TX 78751
- Friday, April 24, 2020 (Brown-Heatly Building)
- Friday, July 24, 2020 (Brown-Heatly Building)
- Friday, Oct. 21, 2020 (Brown-Heatly Building)
Public Hearing Room
4900 N Lamar Blvd.
Austin, TX 78751-2316
Board meetings will convene at the Brown-Heatly Building in Austin, unless otherwise announced. Visitor parking is on the 5th and 6th floor of the parking garage. Visitors enter the building at the south entrance and check in at the security station. People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact HHSC at least 72 hours before the meeting so appropriate arrangements can be made.
- Directions to Main Headquarters
- Map of HHSC campus (PDF) - includes Brown-Heatly, Moreton, and Winters buildings and parking locations
The public can submit written testimony for consideration by board members. All submitted materials are reviewed by the board prior to each meeting. To have your testimony reviewed it must be submitted with a completed Written Testimony Registration to HHSC via mail or e-mail and received within five (5) business days after the meeting's agenda has been announced online. Materials may not exceed ten (10) pages. If the submitted materials are mailed the submitter must provide 25 copies. Please contact HHSC to learn about submitting written testimony to the board. Audiovisual equipment and promotional or marketing materials are not allowed.
The board shall permit public comment on any action item under consideration by the board, including, but not limited to, any changes to the preferred drug list, the adoption of or changes to drug use criteria, adoption of clinical prior authorization criteria, or drug utilization review retrospective proposals. Any testimony on non-actionable issues may be disallowed by the Chair. Testimony is limited to three (3) minutes at the discretion of the Chair. Please ensure the information presented is new and relevant to the agenda item for board review.
Members of public who wish to testify must complete and submit a Public Testimony Registration to HHSC on the day of the meeting. The form is available online 10 days prior to meeting and the day of the meeting. Forms are only accepted during the following registration times:
- Between 8 and 9 a. m. for agenda items scheduled for public comment prior to the executive work session (i.e. preferred drug list)
- Between 11:30 a. m. and 12:30 p. m. for agenda items scheduled for public comment after the executive session (i.e. retrospective and prospective drug utilization)
All registrants must identify on the form their name, address, phone number, occupation, and represented organization, any direct or indirect compensation, as well as the drug or drug class for which testimony will be provided. HHSC staff will be available on the day of the meeting to receive the form and ensure all information has been provided. Audiovisual equipment and promotional or marketing materials are not allowed.
November 18, 2019
October 2019 Drug Utilization Review Board Meeting Summary
November 6, 2019
October 2019 Preferred Drug List Recommendations Now Available
November 4, 2019
2020 Drug Utilization Review Board Schedule Available
October 23, 2019
Anticonvulsant Therapeutic Class Update for Oct. DUR Board Meeting